Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.44 |
| ▸ | LIG1 | P18858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357094 | 1.00 | HPGD (0.52) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL1004754 | 0.84 | HPGD (0.46) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL308224 | 0.84 | HPGD (0.46) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL7026922 | 0.79 | KMT2A (0.48) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL2817419 | 0.79 | HPGD (0.56) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL6401253 | 0.78 | TDP1 (0.56) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL6046218 | 0.78 | TDP1 (0.56) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL717977 | 0.78 | TDP1 (0.56) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL4196339 | 0.77 | HPGD (0.54) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL7124543 | 0.75 | HPGD (0.52) | HPGDKDM4EALDH1A1SMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080524-A | Anti-yellowing antibacterial composite material particle and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-4436538-A1 | COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION | Merryvital AG (CH) | 2024-10-02 | — | — | EP | claimed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | claimed |
| WO-2023094852-A1 | COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION | MERRYVITAL AG (CH) | 2023-06-01 | — | — | WO | claimed |
| EP-3634430-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2020-04-15 | — | — | EP | claimed |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | KINTAI THERAPEUTICS, INC. | 2020-04-02 | — | — | US | claimed |
| CN-110869024-A | Multi-biological agents and methods of use thereof | 旗舰创业创新五公司 | 2020-03-06 | — | — | CN | claimed |
| US-20190308031-A1 | SKIN DISORDER THERAPEUTICS AND METHODS OF USE | SYMBIOME, INC. | 2019-10-10 | — | — | US | claimed |
| WO-2018226732-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2018-12-13 | — | — | WO | claimed |
| US-20170087116-A1 | Treatment of Inflammatory and Infectious Skin Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-03-30 | — | — | US | claimed |
| US-6479466-B1 | Compositions for treating viral infections, and methods therefor | UNIVERSITY OF MARYLAND | 2002-11-12 | — | — | US | claimed |
| CN-1377262-A | Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses | PROCTER & GAMBLE (US) | 2002-10-30 | — | — | CN | claimed |
| EP-1234571-A1 | Topical composition containing a hydroxystilbene and a polyol | L'OREAL (FR) | 2002-08-28 | — | — | EP | claimed |
| EP-1221949-A2 | METHOD AND COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-LIKE ILLNESSES | THE PROCTER & GAMBLE COMPANY (US) | 2002-07-17 | — | — | EP | claimed |
| EP-1140097-A4 | PRODUCTS COMPRISING TRIHYDROXYSTILBENES AND DERIVATIVES THEREOF AND METHODS FOR THEIR MANUFACTURE AND USE | PURE WORLD BOTAN INC (US) | 2002-05-08 | — | — | EP | claimed |
| US-6361815-B1 | ISOLATION OF PURIFIED PRODUCT COMPRISING 85% BY WEIGHT OF 3,4',5-TRIHYDROXY-TRANS-STILBENE FROM PLANT MATERIAL CONTAINING TRIHYDROXYSTILBENES AND GLYCOSYLATED DERIVATIVES THEREOF | PURE WORLD BOTANICALS, INC. | 2002-03-26 | — | — | US | claimed |
| EP-1140097-A2 | PRODUCTS COMPRISING TRIHYDROXYSTILBENES AND DERIVATIVES THEREOF AND METHODS FOR THEIR MANUFACTURE AND USE | Pure World Botanicals, Inc. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2001008671-A2 | METHOD AND COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-LIKE ILLNESSES | THE PROCTER & GAMBLE COMPANY (US) | 2001-02-08 | — | — | WO | claimed |
| WO-2000037021-A2 | PRODUCTS COMPRISING TRIHYDROXYSTILBENES AND DERIVATIVES THEREOF AND METHODS FOR THEIR MANUFACTURE AND USE | PURE WORLD BOTANICALS, INC. (US) | 2000-06-29 | — | — | WO | claimed |
| EP-0773020-A2 | Pharmaceutical compositions containing L-carnitine or derivatives thereof in combination with resveratrol or derivatives thereof, for the prophylaxis and treatment of cardiovascular disorders, peripheral vascular diseases and peripheral diabetic neuropathy | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1997-05-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | HPGD 1813/4885KDM4E 2438/4885ALDH1A1 1112/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | HPGD 1813/4885KDM4E 2438/4885ALDH1A1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.